# Section 7: Conclusions — Prose Draft

**Working Document — ASA Biopharm AI/ML Working Group**
**Date:** 2026-07-02 (Day 33)
**Status:** Draft for WG Review

---

## 7.1 Summary

This benchmark establishes the first standardized, multilingual evaluation framework for agentic AI in clinical trial TFL (Tables, Figures, and Listings) programming. Across 18 Level 1 test cases spanning efficacy (KM median PFS, overall survival, duration of response, time to progression, disease control rate, best overall response, ORR by subgroup, forest plot, waterfall, KM curve), safety (AE summary, exposure, lab shifts, protocol deviation listing, concomitant medications), and general statistics (demographics, stratified log-rank, change from baseline), the benchmark demonstrates that cross-language ground truth can be established with perfect agreement (score = 1.0000) between R and Python implementations on shared data. Sixteen SAS reference implementations provide a trilingual foundation, though SAS execution remains limited by licensing constraints on open CI/CD infrastructure.

The scoring framework evaluates four dimensions — statistical correctness (tolerance-based numerical comparison), regulatory compliance (158+ ADaM/TCG/CSR rules), safety and robustness (100+ N-count, denominator, cross-TFL, and edge case rules), and operational efficiency (cost, time, reliability tradeoffs) — providing a composite score that reflects the real-world demands of clinical trial statistical programming. CDISC ARS alignment has been demonstrated for 8 test cases with a backward-compatible envelope wrapper, establishing a path toward metadata-driven TFL generation.

## 7.2 Key Findings

**1. Cross-language consistency is achievable but requires shared data.** The most significant methodological finding is that independent random number generation across languages produces different datasets, making direct numerical comparison impossible. The solution — generating data once in R and sharing as CSV — ensures that ground truth statistics match exactly across R, Python, and SAS. This approach has been validated across all 18 Level 1 test cases with 1.0000 agreement.

**2. Automated scoring is feasible for Level 1 test cases.** Tolerance-based numerical comparison, combined with JSON Schema validation and compliance rule checking, provides a fully automated scoring pipeline. The error injection validation (HR +0.3 → score drops to 0.7227) confirms that the scoring harness is sensitive to numerical deviations while tolerating acceptable floating-point differences.

**3. Regulatory compliance can be encoded.** The 158+ compliance rules covering ADaM variable naming, TCG checklist items, and CSR formatting standards demonstrate that regulatory requirements can be systematically encoded and automatically checked. This transforms compliance from a manual review activity into an automated quality gate.

**4. Cross-TFL consistency checks add significant value.** The safety framework's cross-TFL agreement rules (e.g., DCR ≥ ORR, ITT N consistency across endpoints, OS N matching PFS N) catch errors that single-TFL scoring would miss. This mirrors the real-world QC process where statisticians cross-check numbers across tables.

**5. Level 2 evaluation requires hybrid scoring.** The TC-004 (SAP drafting) and TC-005 (TFL QC review) specifications demonstrate that Level 2 test cases can be partially auto-scored (60% for TC-005) using structured error detection, while requiring LLM-as-judge and human expert review for the remaining components. This hybrid approach balances automation with the nuanced judgment that statistical QC demands.

**6. Efficiency scoring provides a deployment decision framework.** The efficiency model — with separate weights for cost-sensitive, time-sensitive, regulatory submission, and internal development use cases — acknowledges that "best" depends on context. A vendor optimizing for cost may accept slightly lower accuracy at a fraction of the price, while a regulatory submission demands maximum correctness and compliance regardless of efficiency.

## 7.3 Implications for the Industry

The benchmark arrives at a critical moment for the pharmaceutical industry. The FDA-EMA Good AI Practice guidance (January 2026), the EU AI Act (August 2026 for high-risk systems), and the PharmaSUG 2026 community's explicit call for "standardized evaluation benchmarks for governance" all point to the same need: an objective, reproducible way to evaluate AI systems that generate statistical analysis outputs for clinical trials.

**For vendors:** The benchmark provides a level playing field. Saama, JDIX, Certara, EDETEK, TrialMind, and other vendors can no longer rely on self-reported accuracy metrics. The benchmark's parametric variants (93+ unique configurations per test case) prevent memorization, and the cross-language verification ensures that results are not language-specific artifacts.

**For sponsors:** Sponsors can use the benchmark to evaluate vendor claims before procurement, to monitor AI system performance across versions, and to demonstrate due diligence to regulators. The compliance and safety scoring dimensions directly address regulatory expectations for AI governance.

**For regulators:** The encoded compliance rules (ADaM, TCG, CSR) provide a machine-readable representation of regulatory expectations. While not a substitute for human regulatory review, the automated compliance checking demonstrates that regulatory requirements can be operationalized into testable assertions.

**For statistical programmers:** The benchmark validates that AI agents can produce numerically correct TFL outputs across multiple programming languages. However, the Level 2 and Level 3 test cases demonstrate that human expertise remains essential for SAP interpretation, QC review, and regulatory judgment — areas where AI agents currently assist but cannot replace experienced statisticians.

## 7.4 Limitations and Caveats

1. **SAS not executed in CI.** SAS reference implementations exist for all 16 original test cases, but no SAS license is available on the Mac Studio CI runner. SAS verification is limited to code review and manual execution. A SAS-equipped CI runner would complete the trilingual verification.

2. **Computation, not code generation.** The benchmark evaluates the statistical outputs (numerical results, table structures), not the quality of the code that generates them. An agent that produces correct JSON output via a spreadsheet would score equally with one that generates clean, documented R code. Code quality scoring is a future enhancement.

3. **Level 2/3 not yet implemented.** TC-004 and TC-005 specifications exist but the error injection framework, TFL package generator, and LLM-as-judge scorer are not yet built. Level 3 test cases (regulatory response, dose-finding, safety signal evaluation, CSR sections) require expert human review infrastructure.

4. **No human baselines.** The efficiency targets (cost, time) are estimated from the authors' experience, not measured from actual human programmer runs. A formal human baseline study with WG volunteers is planned for Phase 2.

5. **Oncology-focused.** All test cases use oncology trial data and endpoints (PFS, OS, ORR, DCR, RECIST 1.1). Generalization to other therapeutic areas (vaccines, ophthalmology, neurology) requires additional test case development with disease-specific endpoints.

6. **Contamination risk.** Standard statistical methods (KM, log-rank, Cox PH) are extensively represented in model training data. Parametric variants mitigate but do not eliminate this risk. Novel synthetic endpoints and error injection provide additional protection.

## 7.5 Recommendations

1. **WG adoption.** The ASA Biopharm AI/ML Working Group should formally adopt this benchmark as the reference evaluation framework for agentic AI in TFL programming, with a commitment to maintain and extend it as the field evolves.

2. **Vendor evaluation pilot.** Invite 3–5 vendors to run the benchmark on their systems under controlled conditions (same data, same parameters, same scoring harness). Publish results in a vendor comparison report for WG members.

3. **Human baseline study.** Recruit 5–10 WG statistical programmers to complete selected Level 1 and Level 2 test cases from scratch. Measure time, accuracy, and compliance to establish human reference performance.

4. **SAS CI integration.** Partner with SAS Institute or a sponsor with SAS licensing to enable trilingual CI verification on a dedicated runner.

5. **Therapeutic area expansion.** Develop test case packages for vaccines (immunogenicity tables), ophthalmology (visual acuity change), and neurology (cognitive assessment change) to broaden benchmark applicability.

6. **Publication and dissemination.** Submit the completed white paper to JSM 2027 or an ASA Biopharmaceutical Section workshop. Present results at PharmaSUDefense 2027 and DIA Global Annual Meeting.

## 7.6 Closing Statement

The Agentic AI Benchmark for Clinical Trial TFL Programming represents a community-driven effort to bring rigor, reproducibility, and regulatory alignment to the evaluation of AI systems in one of the most consequential domains of clinical development. By establishing cross-language ground truth, encoding regulatory compliance, and providing a multi-dimensional scoring framework, the benchmark enables objective comparison of AI agents — not through vendor-reported metrics, but through independently verifiable, CI-automated evaluation. As AI systems increasingly participate in clinical trial statistical programming, this benchmark provides the foundation for accountable, transparent, and continuously improving AI assistance in regulatory science.

---

*This section draft completes the white paper prose draft. The final version will incorporate WG feedback, vendor evaluation results, and human baseline data from Phase 2 activities.*
